These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 25714390)

  • 1. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
    Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
    Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H
    Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination.
    Thabuis A; Tararbit K; Taha MK; Dejour-Salamanca D; Ronin V; Parent du Chatelet I; Spaccaferri G
    Euro Surveill; 2018 Jul; 23(28):. PubMed ID: 30017022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.
    Lee HJ; Choe YJ; Hong YJ; Kim KH; Park SE; Kim YK; Oh CE; Lee H; Song H; Bock H; Casula D; Bhusal C; Arora AK
    Vaccine; 2016 Feb; 34(9):1180-6. PubMed ID: 26826544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study.
    Mensah AA; Campbell H; Clark SA; Ribeiro S; Lucidarme J; Bai X; Borrow R; Ladhani SN
    Lancet Child Adolesc Health; 2023 Mar; 7(3):190-198. PubMed ID: 36736341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.
    Castilla J; García Cenoz M; Abad R; Sánchez-Cambronero L; Lorusso N; Izquierdo C; Cañellas Llabrés S; Roig J; Malvar A; González Carril F; Boone ALD; Pérez Martín J; Rodríguez Recio MJ; Galmés A; Caballero A; García Rojas A; Juanas F; Nieto M; Viloria Raymundo LJ; Martínez Ochoa E; Rivas AI; Castrillejo D; Moreno Pérez D; Martínez A; Borràs E; Sánchez Gómez A; Pastor E; Nartallo V; Arteagoitia JM; Álvarez-Fernández B; García Pina R; Fernández Arribas S; Vanrell J; García Hernández S; Mendoza RM; Méndez M; López-Tercero MM; Fernández-Rodríguez Á; Blanco Á; Carrillo de Albornoz FJ; Ruiz Olivares J; Ruiz-Montero R; Limia A; Navarro-Alonso JA; Vázquez JA; Barricarte A
    N Engl J Med; 2023 Feb; 388(5):427-438. PubMed ID: 36724329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
    Beck E; Klint J; Neine M; Garcia S; Meszaros K
    Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.